A very difficult question to answer. SCS was the most publicize product in terms of where this company was regarding the approval needed from FDA. Now LIberty adds to the portfolio of products.
The market seems to be waiting for confirmation about these products technology in order to push the price further.
An announcement regarding SCS is probable soon. Once SCS proves merit most likely the price will surge again. Yet another finance announcement is also possible.
Personally $35 per share within the next two years is my expectation.
News 
Market Data 
Discover 
